Saturday 17 October 2026
Export CODX’s income statement to Excel — free account
Co-Diagnostics, Inc.
CODX Healthcare Medical Devices
Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.
0.65
0.07
−9.72%
Follow CODX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
18.52 | 5.84 | 10.83 | 25.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.87) | (0.53) | (1.09) | (2.21) | |
P/B ratio |
1.05 | 0.26 | 0.33 | 0.33 | |
Price to Tangible BV |
2.43 | 0.48 | 0.50 | 0.95 | |
EV/Sales |
13.46 | (5.62) | (8.26) | 3.11 | |
EV/EBITDA |
0.00 | 0.08 | 0.10 | 0.00 | |
EV/Operating CF |
(0.36) | 0.14 | 0.18 | (0.05) | |
EV/FCF |
(0.35) | 0.14 | 0.17 | (0.05) | |
Quick Ratio |
1.29 | 1.94 | 3.42 | 3.36 | |
Current Ratio |
1.81 | 2.28 | 3.87 | 3.81 | |
Net Debt/EBITDA |
0.61 | 0.92 | 0.45 | 1.70 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF/Net income |
1.14 | 0.86 | 0.24 | 1.00 | |
Capex/Depreciation |
(0.09) | (0.56) | (0.49) | (0.28) | |
Research and Development Expense of Revenue |
2,499.88% | 4,064.45% | 1,932.21% | 3,081.64% | |
Selling, General and Administrative Expense of Revenue |
1,184.53% | 2,035.00% | 915.01% | 1,640.23% | |
Intangible Assets out of Total Assets |
0.44 | 0.34 | 0.29 | 0.58 | |
Share Based Compensation of Revenue |
128.72% | 150.07% | 110.65% | 344.29% | |
Graham Net Nets |
0.10 | 1.03 | 1.42 | 0.70 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(866.39%) | (1,736.83%) | (699.25%) | (288.08%) | |
Free Cash Flow Yield |
(205.60%) | (691.59%) | (442.41%) | (244.28%) | |
Revenue per Share |
0.04 | 0.06 | 0.20 | 0.12 | |
Operating CF per Share |
(1.66) | (3.48) | (4.66) | (4.68) | |
Capex per Share |
0.00 | (0.06) | (0.10) | (0.06) | |
Free Cash Flow per Share |
(1.66) | (3.54) | (4.76) | (4.74) | |
Cash per Share |
0.85 | 3.65 | 8.93 | 9.07 | |
Shareholders Equity per Share |
2.95 | 7.12 | 15.51 | 31.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.95 | 7.12 | 15.51 | 31.56 | |
Free Cash Flow |
(7.17) | (7.99) | (6.33) | (5.98) | |
Working Capital |
2.33 | 5.50 | 10.15 | 10.36 | |
Capital Expenditures |
(0.02) | (0.14) | (0.13) | (0.08) | |
Net Current Asset Value |
1.31 | 4.33 | 9.58 | 9.14 | |
EV/EBIT |
0.00 | 0.08 | 0.10 | 0.00 | |
Capex to Sales |
0.11 | 0.97 | 0.50 | 0.52 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.13 | 0.11 | 0.18 | 0.58 | |
Average Payables |
1.36 | 2.37 | 2.59 | 1.82 | |
Average Inventory |
0.96 | 0.96 | 1.03 | 1.18 | |
Average Assets |
31.53 | 38.32 | 44.15 | 58.56 | |
Average Common Equity |
26.93 | 31.98 | 37.25 | 51.81 |
Columns are period end dates